Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Atopic dermatitis (AD) is a common skin disease that has increased in prevalence worldwide
two- to threefold over the last 50 years. Epiceram, a newly FDA-approved medical device is a
topical barrier repair cream designed to deliver special epidermal lipids to the top layers
of the skin in order to correct skin barrier abnormalities found in atopic dermatitis.
Epiceram does not contain corticosteroids or other conventional anti-inflammatory components
and represents a novel class of skin barrier repair therapy for inflammatory skin disease.
The objective of this study is to determine whether Epiceram is a safe and effective therapy
for mild to moderate atopic dermatitis and whether it may serve as an alternative to Elidel
therapy.